1 research outputs found
Antigiardial activity of novel triazolyl-quinolone-based chalcone derivatives:when oxygen makes the difference
Giardiasis is a common diarrheal disease worldwide caused by the protozoan parasite
Giardia intestinalis. It is urgent to develop novel drugs to treat giardiasis, due to
increasing clinical resistance to the gold standard drug metronidazole (MTZ). New
potential antiparasitic compounds are usually tested for their killing efficacy against G.
intestinalis under anaerobic conditions, in which MTZ is maximally effective. On the
other hand, though commonly regarded as an ‘anaerobic pathogen,’ G. intestinalis
is exposed to relatively high O2 levels in vivo, living attached to the mucosa of the
proximal small intestine. It is thus important to test the effect of O2 when searching
for novel potential antigiardial agents, as outlined in a previous study [Bahadur et al.
(2014) Antimicrob. Agents Chemother. 58, 543]. Here, 45 novel chalcone derivatives
with triazolyl-quinolone scaffold were synthesized, purified, and characterized by high
resolution mass spectrometry, 1H and 13C nuclear magnetic resonance and infrared
spectroscopy. Efficacy of the compounds against G. intestinalis trophozoites was tested
under both anaerobic and microaerobic conditions, and selectivity was assessed in a
counter-screen on human epithelial colorectal adenocarcinoma cells. MTZ was used as
a positive control in the assays. All the tested compounds proved to be more effective
against the parasite in the presence of O2, with the exception of MTZ that was less
effective. Under anaerobiosis eighteen compounds were found to be as effective as
MTZ or more (up to three to fourfold); the same compounds proved to be up to >100-
fold more effective than MTZ under microaerobic conditions. Four of them represent
potential candidates for the design of novel antigiardial drugs, being highly selective
against Giardia trophozoites. This study further underlines the importance of taking O2
into account when testing novel potential antigiardial compounds